Compare DexCom, Inc. (DXCM) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nucor Corporation — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Nucor Corporation trades at $250.33 (market cap $55.84B). The key difference: Nucor Corporation is the larger of the two by market cap, and Nucor Corporation pays a 0.91% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nucor Corporation for 78 Days on average.
| DXCM | NUE | |
|---|---|---|
Market Cap | $31.86B | $55.84B |
Volume | 3,607,070 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $274.74 |
52-Week Low | $54.84 | $131.78 |
Typical Hold Time | 62 Days | 78 Days |
Enterprise Value | $31.32B | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Nucor (NUE) trades at $250.33, up 1.58% with a mixed technical picture showing bearish moving averages but neutral oscillators. The company delivered strong Q2 2026 earnings of $4.84 EPS, beating expectations, and projects higher Q3 earnings on improved steel pricing. Revenue has stabilized at $32.49B in 2025 after declines from 2022 peaks, with net margins improving to 7.99%. Analyst consensus remains positive with a $266.88 price target and 57.58% buy ratings.
Nucor presents a balanced opportunity with strong operational performance and shareholder returns through dividends, though facing headwinds from competitive pressures and cyclical steel demand. The stock's valuation appears reasonable with P/E of 19.64 and P/S of 1.56, but investors should monitor execution against Q3 guidance and industry capacity expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
